BiotechTube

KPS-0373, High dose + KPS-0373, Low dose + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Spinocerebellar Degeneration

Conditions

Spinocerebellar Degeneration

Trial Timeline

Oct 9, 2013 → Jan 1, 2015

NCT ID
NCT01970098

About KPS-0373, High dose + KPS-0373, Low dose + Placebo

KPS-0373, High dose + KPS-0373, Low dose + Placebo is a phase 3 stage product being developed by Kissei Pharmaceutical for Spinocerebellar Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT01970098. Target conditions include Spinocerebellar Degeneration.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01970098Phase 3Completed

Competing Products

15 competing products in Spinocerebellar Degeneration

See all competitors
ProductCompanyStageHype Score
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
76
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
76
KPS-0373 + PlaceboKissei PharmaceuticalPhase 3
76
KPS-0373 + PlaceboKissei PharmaceuticalPhase 2
51
KPS-0373 + PlaceboKissei PharmaceuticalPhase 3
76
KPS-0373Kissei PharmaceuticalPhase 2
51
KPS-0373, High dose + KPS-0373, Low doseKissei PharmaceuticalPhase 3
76
varenicline + placeboPfizerPhase 2
51
BIIB132 + BIIB132-Matching PlaceboBiogenPhase 1
30
IVIGBaxterPhase 2
49
Intravenous Immune Globulin (IVIG)BaxterPhase 1
30
ARO-ATXN2 Injection + PlaceboArrowhead PharmaceuticalsPhase 1
30
Troriluzole + Placebo + TroriluzoleBiohavenPhase 2/3
60
BHV-4157BiohavenPre-clinical
18
troriluzole + PlaceboBiohavenPhase 3
72

Other Products from Kissei Pharmaceutical

KAD-1229 + Placebo + InsulinApproved
84
Avacopan, prednisolone and rituximab + Prednisolone and rituximabApproved
84
KLH-2109 + LeuprorelinPhase 3
76
KAD-1229Phase 3
76
KUC-7483 + Placebo + TolterodinePhase 3
76